Business Fortune
Cancer, with its complex biology and ever-evolving tactics, has long been a formidable challenge for both patients and researchers. Yet, with new scientific insights, hope is on the horizon. Volastra, a clinical-stage biotechnology company based in New York City, is on the cutting edge of cancer research, specifically targeting chromosomal instability (CIN), a critical vulnerability in many cancer types. Through groundbreaking work in oncology therapeutics, Volastra is reshaping the landscape of cancer treatment, offering new avenues for patients with some of the most difficult-to-treat cancers.
A Vision to Conquer Cancer
Volastra was founded with a singular goal: to harness the power of chromosomal instability (CIN) as a weapon against cancer. Over the past century, cancer researchers have viewed the chaotic behavior of chromosomes in cancer cells as a characteristic of the disease—something that simply happens due to the inherent instability of these cells. However, Volastra has disrupted this old paradigm.
The company is transforming the way scientists understand CIN by recognizing that chromosomal instability presents a vulnerability—something that, when properly targeted, can be leveraged to defeat cancer. With a team of world-class scientists and advisors, Volastra is at the forefront of pioneering therapies that could change the course of cancer treatment.
Unveiling the Mystery of Chromosomal Instability (CIN)
At the heart of Volastra’s research lies the concept of chromosomal instability, or CIN. This refers to an elevated rate of errors that occur during cell division, leading to structural and numerical changes in chromosomes. These abnormalities introduce a high degree of genetic diversity in cancer cells, which helps them evade the body’s immune defenses and become resistant to current therapies.
Unlike normal cells, which undergo tightly regulated division processes, cancer cells, due to CIN, often divide uncontrollably, producing cells with abnormal chromosome numbers and structures. This instability not only fuels the cancer’s progression but also its ability to resist treatments.
For years, the chaotic nature of CIN was considered an unavoidable feature of cancer biology. But recent advances have shown that CIN isn’t just a byproduct of cancer—it’s a potential target for new therapies. The proteins and mechanisms that cancer cells rely on to survive this instability are not necessary for normal cells, providing an opportunity to develop selective treatments that target cancer cells without affecting healthy tissue.
Volastra's CINtech: A Revolutionary Approach
What sets Volastra apart from other biotechnology companies is its pioneering approach to cancer treatment: CINtech. CINtech is an innovative research strategy that combines proprietary technology, screening techniques, and computational modeling to understand and target CIN. This cutting-edge method allows Volastra to identify new biomarkers and cancer cell vulnerabilities with a level of precision never before possible.
The company’s research leverages large oncology data sets from decades of cancer studies, using CINtech to uncover novel insights about the specific weaknesses of chromosomally unstable cancer cells. By filtering through this vast trove of information, Volastra is uncovering opportunities for targeted therapies that could offer hope to patients who currently have limited treatment options.
Unlocking Cancer’s Vulnerabilities: Volastra’s Dual Approach
Volastra’s research focuses on two complementary approaches to exploit the vulnerabilities of chromosomally unstable cancers: synthetic lethality and immune activation.
Synthetic Lethality: A Direct Approach to Killing Cancer Cells
Synthetic lethality works by targeting the essential proteins or processes that cancer cells depend on to survive, but which are not necessary for the survival of healthy cells. In this approach, Volastra aims to identify these cancer-specific vulnerabilities and design therapies that kill cancer cells while sparing healthy cells.
A prime example of this is the protein KIF18A, which plays a crucial role in the division of chromosomally unstable cancer cells. Unlike normal cells, which can divide without the need for KIF18A, cancer cells are heavily reliant on this protein to complete mitosis. By inhibiting KIF18A, Volastra’s therapies can prevent cancer cells from dividing, leading to their death without impacting normal cell function.
Immune Activation: Reawakening the Body’s Defenses
The second approach Volastra is pursuing is immune activation. Cancer cells have learned to evade detection by the body’s immune system, which typically identifies and destroys abnormal cells. Volastra’s immune activation strategy aims to reawaken the immune system’s ability to recognize and target chromosomal instability in cancer cells, providing a powerful, indirect way to eliminate these rogue cells.
Looking Ahead: A Future of Hope for Cancer Patients
As Volastra advances its clinical trials and continues to refine its CINtech approach, the future looks bright for patients facing some of the most aggressive and difficult-to-treat cancers. The company’s dedication to unlocking the mysteries of chromosomal instability has the potential to change the way cancer is treated, offering new hope to those who have long been without effective options.
Through its innovative research, precise targeting of cancer vulnerabilities, and commitment to improving patient outcomes, Volastra is poised to become a leader in the biotechnology space. Its groundbreaking work is not only revolutionizing cancer treatment but is also inspiring the broader scientific community to reimagine what is possible in the fight against cancer.
Charles Hugh-Jones, M.D., FRCP | Chief Executive Officer
Charles is an experienced biotech leader and a board-certified physician. Prior to joining Volastra, Charles served as the global chief medical officer at Allergan PLC, where he led complex interdisciplinary teams and supported the launch of novel medicines in multiple therapeutic areas. Before Allergan, Charles worked for Pfizer Oncology as their chief medical officer and had medical oversight of all late-stage drug development and commercialization activities.
Charles received his bachelor’s in neuroanatomy and M.D. from the University of London. He went on to complete higher specialist training in diagnostic radiology.
